Navigation Links
A ray of light on Cardiology

The angiotensin-converting enzyme (ACE) inhibitor ramipril, used for the treatment of hypertension, can retrieve, and may even prevent, left ventricular hypertrophy (LVH), thereby lowering the risk of stroke and myocardial infarction (MI), a new study has shown.Results from the landmark Heat Outcome Prevention Evaluation (HOPE) study showed the drug to cause reversal and prevention of LVH in a broad range of patients – those with normal or controlled blood pressure, both with and without coronary heart disease.//

The HOPE study compared the effects of the ACE inhibitor in addition to standard therapy with placebo and vitamin E in a sample of about 7,580 high-risk patients with cardiovascular disease.In the HOPE sub-study, conducted by Dr James Chadwik and colleagues from the University of Baltimore, the electrocardiograms of 6,222 patients at baseline and at the end of the 4.5 year-long study were compared for the presence, regression or development of LVH. Cardiovascular outcomes such as MI, stroke and heart failure were also evaluated.

Among 92.9 per cent of the patients, ramipril either prevented or caused gradual regression of LVH, independent of its effect on blood pressure control. Adverse cardiovascular outcomes were also lower among those who did not develop LVH or experienced regression of their LVH, compared with those in which LVH developed or did not regress. However, 91 per cent of the patients who received a placebo experienced prevention or regression of LVH, which the researchers said was “intriguing” but was more likely to be due to other risk factor modifications among the study participants.

Since the regression of LVH found with the drug was independent of blood pressure reduction, the study authors suspect that ACE inhibitors have a direct effect in causing regression.Dr Gregory Bosen, professor of cardiovascular medicine at City Hospital in England, agrees that the research raises important issues. Dr Chadw ik said that monitoring changes in LVH status by ECG might predict outcomes for patients with the condition. “We think we can now reduce the risk of cardiovascular events and death by regression of LVH using ECG markers. The ECG is easily applied and relatively inexpensive.”

'"/>




Related medicine news :

1. Doctors operate upon patients in candlelight- latest from the quake scene
2. “Don’t fear long haul flights!” Vascular surgeon tells travelrs
3. Hazards of sunlight
4. Slightly High BP Poses Health Risk
5. Arterial stiffness prevented by light drinking
6. New light on Cardiology
7. Diet, Sunlight connected to Breast Cancer Risk
8. Dangers of sunlight
9. Nightlights could ward diabetic blindness
10. Unborn babies respond to light
11. Sensitive to bright light? You may have sensitive teeth also
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/24/2017)... , ... January 24, 2017 , ... ... provider of enterprise software products, today announced a strategic partnership with Lucidworks ... users to access and analyze their Fusion platform for building powerful enterprise search ...
(Date:1/24/2017)... Santa Rosa, California (PRWEB) , ... January 24, 2017 , ... ... named Cary McNamara as chief financial officer. , “Cary’s broad financial ... individual who possesses both the strategic planning and day-to-day financial operations skills we need ...
(Date:1/24/2017)... , ... January 24, 2017 , ... The Cruise ... Cruises as part of the line’s 4th Annual MSC True Partnerships’ Awards. ... North American travel partners for the year based on overall business growth in revenue ...
(Date:1/24/2017)... ... 24, 2017 , ... Twelve startups have been selected from ... Cup Entrepreneurship Competition. Chaired by Under Armour Founder and CEO Kevin Plank, the ... their businesses on February 6, 2017, at Under Armour’s global headquarters in Baltimore, ...
(Date:1/24/2017)... , ... January 24, 2017 , ... ... announced today that its annual Solutions Series of webinars will start January 31 ... leaders discussing a number of current health and benefits topics, including employee engagement, ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... SAN FRANCISCO , Jan. 24, 2017 /PRNewswire/ ... formerly Clontech Laboratories, Inc.), a wholly owned subsidiary of ... In-Fusion® Cloning Primer Design Tool, powered by TeselaGen Biotechnology, ... is a unique method that seamlessly joins together linear ... free, online primer design tool facilitates easy design and ...
(Date:1/24/2017)... 2017 Sherpa Clinical Packaging ( www.sherpaclinical.com ... is pleased to announce the appointment of Kevin Rosenthal as ... Sherpa team to lead Sherpa,s Operations group and ... excellence. Kevin is not new to ... He has extensive experience working for leading pharma ...
(Date:1/24/2017)... Pa. , Jan. 24, 2017   ... 2 biopharmaceutical company developing novel therapies for the ... today announced the appointment of four world-class key ... These new appointments join QR Pharma,s previous roster ... leadership and direction to support the development of ...
Breaking Medicine Technology: